A type IV collagenase inhibitor, N-hydroxy-3-phenyl-2-(4-phenylbenzenesulfonamido) propanamide (BiPS), suppresses skin injury induced by sulfur mustard

Published on Aug 15, 2020in Toxicology and Applied Pharmacology4.219
· DOI :10.1016/J.TAAP.2020.115078
Yoke-Chen Chang7
Estimated H-index: 7
(RU: Rutgers University),
Rita A. Hahn8
Estimated H-index: 8
(RU: Rutgers University)
+ 2 AuthorsDonald R. Gerecke19
Estimated H-index: 19
(RU: Rutgers University)
Sources
Abstract
Abstract Sulfur mustard (SM) is a highly toxic blistering agent thought to mediate its action, in part, by activating matrix metalloproteinases (MMPs) in the skin and disrupting components of the basement membrane zone (BMZ). Type IV collagenases (MMP-9) degrade type IV collagen in the skin, a major component of the BMZ at the dermal-epidermal junction. In the present studies, a type IV collagenase inhibitor, N-hydroxy-3-phenyl-2-(4-phenylbenzenesulfonamido) propanamide (BiPS), was tested for its ability to protect the skin against injury induced by SM in the mouse ear vesicant model. SM induced inflammation, epidermal hyperplasia and microblistering at the dermal/epidermal junction of mouse ears 24–168 h post-exposure. This was associated with upregulation of MMP-9 mRNA and protein in the skin. Dual immunofluorescence labeling showed increases in MMP-9 in the epidermis and in the adjacent dermal matrix of the SM injured skin, as well as breakdown of type IV collagen in the basement membrane. Pretreatment of the skin with BiPS reduced signs of SM-induced cutaneous toxicity; expression of MMP-9 mRNA and protein was also downregulated in the skin by BiPS. Following BiPS pretreatment, type IV collagen appeared intact and was similar to control skin. These results demonstrate that inhibiting type IV collagenases in the skin improves basement membrane integrity after exposure to SM. BiPS may hold promise as a potential protective agent to mitigate SM induced skin injury.
📖 Papers frequently viewed together
2000
4 Authors (M. Mol, ..., Henk P. Benschop)
References72
Newest
#1Patricia Rousselle (University of Lyon)H-Index: 46
#2Jean-Yves Scoazec (University of Paris-Sud)H-Index: 8
Abstract Laminin 332 is crucial in the biology of epithelia. This large extracellular matrix protein consists of the heterotrimeric assembly of three subunits – α3, β3, and γ2 – and its multifunctionality relies on a number of extracellular proteolytic processing events. Laminin 332 is central to normal epithelium homeostasis by sustaining cell adhesion, polarity, proliferation, and differentiation. It also supports a major function in epithelial tissue formation, repair, and regeneration by but...
Source
#1Yoke-Chen ChangH-Index: 7
#2Selina MuhnH-Index: 1
Last. Donald R. GereckeH-Index: 19
view all 5 authors...
Source
#1Gregg B. Fields (FAU: Florida Atlantic University)H-Index: 72
The pursuit of matrix metalloproteinase (MMP) inhibitors began in earnest over three decades ago. Initial clinical trials were disappointing, resulting in a negative view of MMPs as therapeutic targets. As a better understanding of MMP biology and inhibitor pharmacokinetic properties emerged, it became clear that initial MMP inhibitor clinical trials were held prematurely. Further complicating matters were problematic conclusions drawn from animal model studies. The most recent generation of MMP...
Source
#1Sho Hiroyasu (VCH: Vancouver Coastal Health)H-Index: 9
#2Christopher T. Turner (VCH: Vancouver Coastal Health)H-Index: 13
Last. David J. Granville (VCH: Vancouver Coastal Health)H-Index: 51
view all 4 authors...
Pemphigoid diseases are a subgroup of autoimmune skin diseases characterized by widespread tense blisters. Standard of care typically involves immunosuppressive treatments, which may be insufficient and are often associated with significant adverse events. As such, a deeper understanding of the pathomechanism(s) of pemphigoid diseases is necessary in order to identify improved therapeutic approaches. A major initiator of pemphigoid diseases is the accumulation of autoantibodies against proteins ...
Source
#1René Huber (MHH: Hannover Medical School)H-Index: 15
#2Attili (MHH: Hannover Medical School)H-Index: 1
Last. Ralf LichtinghagenH-Index: 45
view all 9 authors...
Blood sampling with different anticoagulants alters matrix metalloproteinase (MMP-) 9 expression, thus influencing its concentration and diagnostic validity. Here, we aimed to evaluate the effects of different anticoagulants on MMP-9 regulation. MMP-9 expression was assessed in response to ethylenediaminetetraacetic acid, citrate, and high-/low-molecular-weight heparin (HMWH, LMWH) in co-culture experiments using THP-1, Jurkat, and HT cells (representing monocytes, T, and B cells). Triple and do...
Source
#1Patricia Rousselle (University of Lyon)H-Index: 46
#2Marine Montmasson (University of Lyon)H-Index: 2
Last. Cécile Garnier (University of Lyon)H-Index: 1
view all 3 authors...
Abstract The ability of skin to act as a barrier is primarily determined by cells that maintain the continuity and integrity of skin and restore it after injury. Cutaneous wound healing in adult mammals is a complex multi-step process that involves overlapping stages of blood clot formation, inflammation, re-epithelialization, granulation tissue formation, neovascularization, and remodeling. Under favorable conditions, epidermal regeneration begins within hours after injury and takes several day...
Source
#1Yoke Chen Chang (RU: Rutgers University)H-Index: 3
#2Melannie Soriano (RU: Rutgers University)H-Index: 1
Last. Donald R. Gerecke (RU: Rutgers University)H-Index: 19
view all 7 authors...
Abstract Sulfur mustard (2,2′-dichlorodiethyl sulfide, SM) is a chemical warfare agent that generates an inflammatory response in the skin and causes severe tissue damage and blistering. In earlier studies, we identified cutaneous damage induced by SM in mouse ear skin including edema, erythema, epidermal hyperplasia and microblistering. The present work was focused on determining if SM-induced injury was associated with alterations in mRNA and protein expression of specific cytokines and chemok...
Source
#1Yoke-Chen Chang (RU: Rutgers University)H-Index: 7
#2Marion K. Gordon (RU: Rutgers University)H-Index: 22
Last. Donald R. Gerecke (RU: Rutgers University)H-Index: 19
view all 3 authors...
Sulfur Mustard (SM) is a potent vesicant or blistering agent. It is a highly reactive bi-functional alkylating agent that cross links proteins, DNA, and other cellular components. Laminin 332 is a heterotrimer glycoprotein and a crucial skin component that attaches the epidermal basal keratinocytes to the dermis. SM wounds histologically appear similar to Epidermolysis Bullosa (EB), human genetic blistering diseases that involve genetic changes in laminin 332. The specific mechanism of action of...
#1Ki M. Mak (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 28
#2Rena Mei (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 1
Basement membranes provide structural support to epithelium, endothelium, muscles, fat cells, Schwann cells, and axons. Basement membranes are multifunctional: they modulate cellular behavior, regulate organogenesis, promote tissue repair, form a barrier to filtration and tumor metastasis, bind growth factors, and mediate angiogenesis. All basement membranes contain type IV collagen (Col IV), laminin, nidogen, and perlecan. Col IV and laminin self-assemble into two independent supramolecular net...
Source
#1Elham Rashidghamat ('KCL': King's College London)H-Index: 5
#2John A. McGrath ('KCL': King's College London)H-Index: 89
: Epidermolysis bullosa (EB) is a clinically and genetically heterogeneous group of inherited blistering diseases that affects ∼ 500,000 people worldwide. Clinically, individuals with EB have fragile skin and are susceptible to blistering following minimal trauma, with mucous membrane and other organ involvement in some subtypes. Within the spectrum of EB, ∼ 5% of affected individuals have the clinically more severe recessive dystrophic (RDEB) variant with a prevalence of 8 per one million of th...
Source
Cited By0
Newest
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.